Data Collection
ascites, death, hepatorenal syndromes, infection, HCC, variceal bleeding
ASCITES, HEPATORENAL SYNDROME, DISEASE, DISORDERS, INFECTION, COMPLICATIONS
Clinical patient data, including age, sex, cause of disease, CTP score, CTP class, MELD score, and laboratory examination results (alanine aminotransferase (ALT), aspartate transaminase (AST), albumin (ALB), total bilirubin (TBIL), prothrombin time (PT), international normalization ratio (INR), creatinine(Cr), and platelet (PLT)), was extracted from their medical records。All subjects were assigned into the SCT group or Non-SCT group according to whether they received HUCB-MSCT during hospitalization. Whether to accept HUCB-MSCT depends on the patient’s own will, there was no subjective artificial choice of doctors. Informed consent was signed prior to stem cell treatment. The survival outcomes and incidence of HCC were obtained by case records and confirmed by telephone calls. Follow-up was performed from the time of hospitalization to October 30, 2021, or the date of death or liver transplantation. HCC was diagnosed according to the Expert Consensus on Standardization of the Management of HCC in China. Abdominal B ultrasonography and CT or MRI scans were performed to exclude other disorders.All patients in the study received standard clinical treatments (including albumin supplementation, coagulation correction, liver protection, antiviral treatment, and necessary anti-infective treatment) and management of complications such as ascites, variceal bleeding, infection, and hepatorenal syndromes according to updated guidelines.